The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis

Freedman, Paul; Schock, Bettina; O’Reilly, Steven

Abstract

Systemic sclerosis (SSc) is an autoimmune connective tissue disease with a triad of features that include vascular abnormalities, inflammation and skin and lung fibrosis. At the core of the disease is the activation of myofibroblasts from quiescent fibroblasts and this can be modified by various cytokines. IL-41 is a recently described cytokine that was initially characterised as an adipokine as it was highly expressed in adipocytes and adipose tissue. However, it has recently been identified as being widely expressed and has immunomodulatory functions. This study examined the circulating levels of IL-41 and its expression in skin biopsies. We demonstrated significantly reduced levels of IL-41 in diffuse SSc that was also mirrored in the skin of SSc patients. AMPK has been proposed as a downstream target of IL-41, so we also measure mammalian target of rapamycin in skin and found that this is elevated in SSc patients. We speculate that IL-41 maybe an antifibrotic cytokine and its reduction may facilitate the activation of fibroblasts.

Citation

Freedman, P., Schock, B., & O’Reilly, S. (2024). The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis. Cells, 13(14), Article 1205. https://doi.org/10.3390/cells13141205

• Journal Article Type: Article
• Acceptance Date: Jul 15, 2024
• Online Publication Date: Jul 17, 2024
• Publication Date: Jul 17, 2024
• Deposit Date: Sep 23, 2024
• Publicly Available Date: Sep 23, 2024
• Journal: Cells
• Electronic ISSN: 2073-4409
• Publisher: MDPI
• Peer Reviewed: Peer Reviewed
• Volume: 13
• Issue: 14
• Article Number: 1205
• DOI: https://doi.org/10.3390/cells13141205
• Public URL: https://durham-repository.worktribe.com/output/2874508